Introduction
============

Neuropathic pain is one of the most common categories of chronic pain and sensory dysfunction affecting a considerable proportion of the global population, negatively influencing their emotional health and overall quality of life ([@b1-etm-0-0-9019]). The prevalence of trauma related to the peripheral nervous system in the United States is 1.3-2.8% ([@b2-etm-0-0-9019]). Neuropathic pain is characterized by a response to non-noxious stimuli (tactile allodynia), spontaneous pain (exaggerated pain response to normal painful stimulus), hyperalgesia and loss of sensation in local areas ([@b3-etm-0-0-9019],[@b4-etm-0-0-9019]). It can be triggered or initiated in the peripheral or central nervous system ([@b5-etm-0-0-9019]). Owing to the complex etiology of neuropathic pain, it is considered to be one of the most challenging pathologies to treat in clinical practice ([@b6-etm-0-0-9019]). At present, most pain medications to treat neuropathic pain are not satisfactory, and cause undesirable side effects. Therefore, it is necessary to find an effective therapy with minimal side effects.

It is well known that α~2~-adrenoceptor (α~2~-AR) agonists have antinociceptive effects in the spinal cord ([@b7-etm-0-0-9019]). α~2~-ARs are located not only in the central nervous system, but also in the peripheral nervous system ([@b8-etm-0-0-9019]). The complex processes involved in α~2~-AR pain regulation have been extensively researched. A previous study demonstrated that α~2~-AR agonists could relieve nerve injury-induced pain by binding to α~2~-AR in patients and animal models with neuropathic pain ([@b9-etm-0-0-9019]). Blockade of spinal 5-hydroxytryptamine (HT)3 receptors reduced α~2~-AR-mediated anti-hypersensitivity by reducing total GABA release ([@b10-etm-0-0-9019]). Furthermore, it is well known that α~2~-AR agonists can enhance the analgesic effects of morphine ([@b11-etm-0-0-9019]). Recently, the α~2~-AR antagonists atipamezole and idazoxan have been shown to block the induction of tolerance to morphine, which was verified through intrathecal atipamezole in opioid naïve and tolerant rats weakening the anti-nociceptive effect of morphine ([@b12-etm-0-0-9019]).

Baicalin is a common flavonoid substance isolated from the root of *Scutellaria baicalensis* Georgi. Previous studies have demonstrated that baicalin possesses anti-inflammatory, antioxidant, antitumor and antiallergy properties ([@b13-etm-0-0-9019]). Furthermore, Chou *et al* ([@b16-etm-0-0-9019]) established the model of carrageenan-evoked thermal hyperalgesia in rats and found that baicalin had a clear analgesic effect. A previous study also demonstrated that baicalin helps relieve pain in patients suffering from osteoarthritis of the knee ([@b17-etm-0-0-9019]).

In this study, it was determined whether baicalin may reduce pain in a spinal nerve ligation rat model of neuropathic pain, and the roles of the peripheral α~2~-AR subtypes in the mechanism of action of baicalin were investigated.

Materials and methods
=====================

### Animals

Male Sprague Dawley rats \[Beijing Vital River Laboratory Animal Technology Co., Ltd.; Charles River Laboratories, Inc.; license no. SCXK9 (Beijing) 20160006; weight, 150-200 g; age, 3 months\] were housed at 22-24˚C and 50-65% humidity on a 12 h light/dark cycle and were provided with free access to food and water. All experiments in this study were conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The procedures were all approved by the Animal Ethics Committee of China Pharmaceutical University (Nanjing, Jiangsu, China), where the study was carried out.

### Neuropathic pain model

Animals were anesthetized with halothane, 1-3% in oxygen, with spontaneous ventilation. A 3 cm paramedian incision was made in the left L4-sacral area, and a bundle of paraspinal muscles was removed to visualize the left L6 transverse process. Using small scissors, the left L6 transverse process was removed completely and the L4-L5 spinal nerves were exposed. After the L4 spinal nerve was separated, the L5 spinal nerve was cut and spread laterally. The fascia and skin were closed using sutures, and the animals were allowed to recover for 10 days prior to the epidural catheterization. Paw withdrawal mechanical threshold (PWT) \<4 g after surgery was recognized as the standard of neuropathic pain induction.

### Drugs administration

A total of 70 rats were randomly divided into the following groups: Control group (n=10); saline group (n=10); baicalin group (n=10); baicalin combined α~2~-AR antagonist groups (n=40). The α~2~-AR antagonist group was subcategorized in to four groups based on the antagonist used, which included the nonselective α~2~-AR antagonist idazoxan (n=10); α~2a~-AR antagonist BRL 44408 (n=10); α~2b~-AR antagonist ARC 239 (n=10); and α~2c~-AR antagonist JP 1302 (n=10). The rats were treated with 20 mg/kg baicalin by intrathecal injection. The drugs used in the study were purchased from Tocris Bioscience. Idazoxan was dissolved in distilled water, and the other drugs were dissolved in physiological saline. All drugs were delivered in a volume of 2 µg/20 µl administered by intrathecal injection. In the control group, the rats did not undergo any surgery. The rats in saline group were injected with physiological saline (10 µl). Drugs were administered once per day for 7 days.

### Behavioral tests

The PWT was measured by the up and down method ([@b18-etm-0-0-9019]). A series of von Frey filaments (0.4, 0.7, 1.2, 2.0, 3.6, 5.5, 8.5 and 15 g) in a perpendicular fashion were used to stimulate the surface of the lateral paw. Each was applied until slightly bent and held for approximately 5 sec. Reponses in the form of sharp withdrawal or paw licking were regarded as a positive response. Only rats with marked allodynia (withdrawal threshold \<4 g) after spinal nerve ligation were studied.

### Expression of α~2~a-AR, α~2~b-AR, α~2~c-AR mRNA in the spinal cord

When the final test was completed, three rats from each experimental group were sacrificed by cervical dislocation whilst anesthetized to obtain the L4-L5 dorsal spinal cord. Tissue samples were frozen immediately at -80˚C. Total RNA in spinal cord tissues was extracted using an RNeasy kit (cat. no. 74104; Qiagen GmbH) following the manufacturer\'s instructions. RNA quality and quantity were measured using a Nanodrop Spectrophotometer (UL-2000; Macylab Instruments, Inc.), while RNA integrity was assessed by gel electrophoresis. A total of 500 ng RNA was used to generate cDNA with a reverse transcription (RT) kit (Takara Biotechnology Co., Ltd.). The temperature conditions for the RT procedure were 65˚C for 10 min, 37˚C for 10 min, 75˚C for 15 min and 37˚C for 20 min. A Mastercycler^®^ nexus X2 (Eppendorf) was used for RT-quantitative (q) PCR (Power SYBR^™^ Green RNA-to-C~T~^™^ 1-step kit, cat. no. 4389986; Thermo Fisher Scientific, Inc.). The thermocycling conditions were 95˚C for 15 sec followed by 35 cycles of 95˚C for 15 sec and 60˚C for 1 min. The relative levels of target mRNAs were standardized to the reference gene β-actin gene. The results were quantified using the 2^-ΔΔCq^ method ([@b19-etm-0-0-9019]). Primers for RT-qPCR in this study were as follows: α~2a~ forward 5\'-GCGCCCCAGAACCTCTTCCTGGTG-3\', reverse 5\'-CCAGCGCCCTTCTTCTCTATGGAG-3\'; α~2b~ forward 5\'-AAACGCAGCCACTGCAGAGGTCTC-3\', reverse 5\'-ACTGGCAACTCCCACATTCTTGCC-3\'; α~2c~ forward 5\'-CTGGCAGCCGTGGTGGGTTTCCTC-3\'; reverse 5\'-GTCGGGCCGGCGGTAGAAAGAGAC-3\'; and β-actin forward 5\'-CGGGAAATCGTGCGTGACAT-3\', reverse 5\'-GAAGGAAGGCTGGAAGAGTG-3\'.

### Quantification of inflammatory mediators in serum

Blood was collected via the tail vein at 72 h after drug injection. Serum inflammatory mediators, including tumor necrosis factor (TNF)-α (cat. no. DY510), interleukin (IL)-6, (cat. no. DY506), IL-17 (cat. no. DY4437) and IL-1β (cat. no. DY401) were tested with ELISA kits supplied by R&D Systems China Co., Ltd. according to the manufacturers\' instructions.

### Histological evaluation

Spinal cord tissues were fixed with 4% paraformaldehyde (Beijing Solarbio Science & Technology Co., Ltd.) at 37˚C for 24 h, dehydrated and then embedded in paraffin wax. The tissues were then cut into 5-µm-thick sections, and stained with hematoxylin and eosin solution (Fuzhou Maixin Biotech Co., Ltd.) at 37˚C for 5 min. Pathological changes were observed under a light microscope (magnification, x400; Nikon Corporation).

### Flow cytometry analyses

The peripheral blood mononuclear cells (PBMC) were separated from blood following the Ficoll 400 and uropolinum density centrifugation method ([@b20-etm-0-0-9019]). The T-lymphocyte subset CD4^+^ was identified by flow cytometry analysis of cells isolated from the PBMCs. PBMCs adjusted to a density of 1x10^6^ cells/ml in complete medium were used for analysis. Phytohemagglutinin solution (25 µl; Cylex, Inc.) was added to block non-specific binding and the cells were incubated for 15-18 h at 37˚C and 5% CO~2~. The frequency of the T-lymphocyte subset was evaluated after staining with the FITC-conjugated mouse anti-rat CD4 (1:100; cat. no. FAB554F, BD Biosciences) at 4˚C for 25 min. After washing, cells were incubated with the pacific blue-A fluorochrome-conjugated isotype control (1:100; cat. no. A10478, Thermo Fisher Scientific, Inc.), to gate nonspecific fluorescence signals, at 4˚C for 25 min. Data were analyzed using FlowJo software (version 7.2.5; FlowJo LLC).

### Statistical analysis

Statistical analysis was implemented using SPSS 20.0 (IBM Corp.). Statistical comparisons between groups were analyzed using one-way ANOVAs followed by Duncan multiple range post hoc tests. All results are reported as the mean ± SD. P\<0.05 was considered to indicate a statistically significant difference. Each test was repeated 3 times.

Results
=======

### Baicalin increases the PWT

Compared with the control group, a significant decrease in PWT was observed in all treatment groups (P\<0.05; [Fig. 1](#f1-etm-0-0-9019){ref-type="fig"}). After baicalin treatment, PWT increased, but the antiallodynic effect of baicalin was antagonized by intrathecal injection of α~2~-AR antagonists. PWT was reduced after 5 days of idazoxan administration when compared to baicalin group (P\<0.05).

### Baicalin contributes to the increase in α~2~-AR mRNA

The expression of α~2a~-AR, α~2b~-AR and α~2c-~AR mRNA were significantly downregulated in the saline group, compared with the control group (P\<0.05; [Fig. 2](#f2-etm-0-0-9019){ref-type="fig"}). Intrathecal administration of baicalin upregulated the levels of α~2~-AR mRNA, especially the levels of α~2a~-AR and α~2c~-AR mRNA (P\<0.05; [Fig. 2A](#f2-etm-0-0-9019){ref-type="fig"} and [C](#f2-etm-0-0-9019){ref-type="fig"}). Compared with baicalin group, the levels of α~2a~-AR, α~2b~-AR and α~2c~-AR mRNA were significantly reduced after the administration of idazoxan (P\<0.05). The antagonist BRL 44408 markedly reduced α~2a~-AR mRNA expression when compared with the baicalin group (P\<0.05; [Fig. 2A](#f2-etm-0-0-9019){ref-type="fig"}). The antagonist ARC239 markedly reduced α~2b~-AR mRNA when compared with the baicalin group (P\<0.05; [Fig. 2B](#f2-etm-0-0-9019){ref-type="fig"}). The antagonist JP1302 markedly reduced α~2c~-AR mRNA expression compared with the baicalin group (P\<0.05; [Fig. 2C](#f2-etm-0-0-9019){ref-type="fig"}).

### Baicalin decreases the levels of TNF-α, IL-6, IL-17 and IL-1β in the serum

As shown in [Fig. 3](#f3-etm-0-0-9019){ref-type="fig"}, the levels of TNF-α, IL-6, IL-17 and IL-1β in the saline group were all markedly higher than those in the control group (P\<0.05). Intrathecal administration of baicalin significantly reduced the levels of TNF-α, IL-6, IL-17 and IL-1β when compared to the saline group (P\<0.05). TNF-α, IL-6 and IL-1β release was significantly increased with idazoxan treatment compared with baicalin group (P\<0.05; [Fig. 3A](#f3-etm-0-0-9019){ref-type="fig"}, [B](#f3-etm-0-0-9019){ref-type="fig"} and [D](#f3-etm-0-0-9019){ref-type="fig"}). TNF-α release was also significantly increased after treatment with BRL44408 and JP1302 (P\<0.05; [Fig. 3A](#f3-etm-0-0-9019){ref-type="fig"}). Treatment with ARC239 also significantly increased IL-6 release (P\<0.05; [Fig. 3B](#f3-etm-0-0-9019){ref-type="fig"}). Treatment with BRL44408 also increased IL-1β release (P\<0.05; [Fig. 3C](#f3-etm-0-0-9019){ref-type="fig"}).

### Histopathological changes in spinal cord tissue

As shown in [Fig. 4A](#f4-etm-0-0-9019){ref-type="fig"}, the distribution of spinal cord neurons was orderly, and the nuclei were clearly visible in the control group. However, the number of neurons decreased and the distribution of neurons was uneven in the saline group ([Fig. 4B](#f4-etm-0-0-9019){ref-type="fig"}). Compared with the saline group, baicalin treatment decreased neuronal apoptosis and reversed the pathomorphology ([Fig. 4C](#f4-etm-0-0-9019){ref-type="fig"}). Intrathecal administration of different α~2~-AR antagonists reversed the effects of the baicalin treatment ([Fig. 4D-G](#f4-etm-0-0-9019){ref-type="fig"}).

### Baicalin decreases the expression of CD4+ cells

To analyze the effects of α~2~-AR expression on CD4^+^ T cells, the percentage of CD4^+^ PBMCs was measured by flow cytometric analysis ([Fig. 5](#f5-etm-0-0-9019){ref-type="fig"}). The results showed that the frequency of CD4^+^ cells was significantly increased in rats following spinal nerve injury (P\<0.05). Compared with the saline group, baicalin treatment suppressed the frequency of CD4^+^ cells (P\<0.05). The administration of different α~2~-AR antagonists appeared to increase the number of CD4^+^ cells compared with that in baicalin group but this difference was not significant.

Discussion
==========

Previous studies have shown that peripheral administration of an α~2~-AR agonist attenuates nociceptive responses in both control animals and hypersensitive animals under neuropathic conditions ([@b20-etm-0-0-9019],[@b21-etm-0-0-9019]). The results of this present study showed that intrathecal injection of baicalin attenuated neuropathic pain induced by spinal cord ligation, and the antiallodynic effects of baicalin were attenuated by α~2~-AR antagonists. This present study revealed that baicalin relieved pain by reducing inflammation, and this beneficial effect may be associated with the expression of α~2~-AR in spinal cord.

A previous study reported that norepinephrine and other α~2a~-AR agonists decreased the release of glutamate in healthy rat dorsal horn synaptosomes, and had analgesic as well as anti-sympathetic effects ([@b22-etm-0-0-9019]). α~2c~-AR was recognized to contribute to spinal cord analgesia induced by α~2~ adrenoreceptor agonists ([@b23-etm-0-0-9019]). Blockade of spinal 5-HT3 receptors reduced α~2~-adrenoceptor-mediated anti-hypersensitivity via reducing total GABA release ([@b24-etm-0-0-9019]). α~2~-AR stimulation induces Gs-mediated acetylcholine release in the dorsal horn after peripheral nerve injury ([@b25-etm-0-0-9019]). In this present study, the expression levels of α~2~-ARs were changed in spinal nerve injury rats, compared to untreated rats. Notably, intrathecal administration baicalin increased α~2a~ and α~2c~-AR mRNA. These results indicated that baicalin relieved the pain by regulating α~2~-AR mRNA levels.

There is increasing evidence demonstrating that neuro- inflammation is one of the pivotal contributors to the development of neuropathic pain. Some pro-inflammatory cytokines produced by microglia in the spinal cord, such as IL-6, IL-17 and IL-1β, play an important role in inflammatory processes ([@b26-etm-0-0-9019]). TNF-α is also a biomarker of acute neuro-inflammatory responses ([@b27-etm-0-0-9019]). The present study showed that the serum levels of TNF-α, IL-6, IL-17 and IL-1β increased after spinal nerve ligation; however, the release of TNF-α, IL-6 IL-17 and IL-1β was reduced by intrathecal administration of baicalin. Furthermore, baicalin treatment appeared to improve the order of nerve fibers and reduced the percentage of CD4^+^ PBMCs. These data suggested that the baicalin was capable of reducing neuropathic pain by regulating the inflammatory response.

In conclusion, this present study indicated that intrathecal administration of baicalin relieved neuropathic pain following spinal nerve ligation in rats. The mechanisms of action may be through upregulating the expression of α~2~-ARs in the spinal cord. This may suggest that baicalin has therapeutic potential for neuropathic pain.
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![Baicalin treatment increases the paw withdrawal threshold, and the antiallodynic effects of baicalin are antagonized by intrathecal injection of α~2~-adrenocetor antagonists. Data are presented as the mean ± SD (n=5). ^\*^P\<0.05, ^\*\*^P\<0.01 vs. the control group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. the saline group, ^∆^P\<0.05 vs. the baicalin group.](etm-20-03-2684-g00){#f1-etm-0-0-9019}

![Effects of baicalin and α~2~-AR antagonists on α~2~-AR mRNA. Baicalin increased the expression of (A) α~2a~-AR mRNA, (B) α~2b~-AR mRNA and (C) α~2c~-AR mRNA. Data are presented as the mean ± SD (n=5). ^\*^P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the saline group; ^∆^P\<0.05 vs. the baicalin group. AR, adrenoceptor.](etm-20-03-2684-g01){#f2-etm-0-0-9019}

![Effects of baicalin and α~2~-AR antagonists on the serum levels of (A) TNF-α, (B) IL-6, (C) IL-17 and (D) IL-1β. Data are presented as the mean ± SD (n=5). ^\*^P\<0.05, ^\*\*^P\<0.01 vs. the control group; ^\#^P\<0.05, ^\#\#^P\<0.01 vs. the saline group; ^∆^P\<0.05 vs. the baicalin group. AR, adrenoceptor; IL, interleukin; TNF, tumor necrosis factor.](etm-20-03-2684-g02){#f3-etm-0-0-9019}

![Baicalin treatment decreases the neuronal apoptosis and reverses the pathomorphology, as observed from spinal cord sections from the (A) control group, (B) saline group, (C) baicalin group, (D) baicalin + idazoxan group, (E) baicalin + BRL 44408 group, (F) baicalin + ARC 239 group and (G) baicalin + JP 1302 group.](etm-20-03-2684-g03){#f4-etm-0-0-9019}

![Effects of baicalin and α~2~-adrenoceptor antagonists on the percentage of CD4^+^ peripheral blood mononuclear cells. Baicalin reduced the percentage of CD4^+^ cells (n=5). ^\*^P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the saline group. Bai, baicalin.](etm-20-03-2684-g04){#f5-etm-0-0-9019}
